Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

Sanford fishes up highest net profit in 10 years
Primary Sector

Sanford fishes up highest net profit in 10 years

David Mair has been its boss for just over a year.

NZ sharemarket down as retail spending stalls in new data
Markets Market Close

NZ sharemarket down as retail spending stalls in new data

April figures from Stats NZ show spending in the retail industry that month was flat.

Tom Raynel 14 May 2025
How Sharesies is providing ‘patient’ capital for listeds
Finance

How Sharesies is providing ‘patient’ capital for listeds

The online platform is being tapped for bookbuilds and dividend reinvestment plans.

NZX rallies 0.87% as tariff uncertainty eases
Markets Market Close

NZX rallies 0.87% as tariff uncertainty eases

Skellerup bounced 4.11% as investors digested easing tariffs. 

Gregor Thompson 13 May 2025